GRAIL Inc (GRAL)

GRAIL became an independent public entity on June 24, 2024, with its stock rising from $15 to $33 per share. In August 2025, GRAIL reported an 11% year-over-year revenue increase and a significant improvement in net loss. In October 2025, GRAIL announced a strategic collaboration with Samsung C&T and Samsung Electronics, accompanied by a $110 million equity investment. Despite these positive developments, insider selling was noted, and analyst sentiment is mixed.

Information regarding the demand seasonality for GRAIL, Inc.'s products and services is limited. However, one report from January 2025 indicated that the third quarter of 2024 was GRAIL's "seasonally weakest quarter" for Galleri test sales.

GRAIL, Inc. is a biotechnology company focused on early cancer detection through blood tests. Its flagship product, the Galleri test, screens for over 50 types of cancer in asymptomatic individuals aged 50 or older. GRAIL also offers DAC tests to aid in cancer diagnosis and provides development services for clinical studies and therapy development.

GRAIL is headquartered in Menlo Park, California, and the Galleri test is commercially available in the United States. The company is expanding into Asian markets through collaborations with Samsung C&T and Samsung Electronics, starting with South Korea. GRAIL is also conducting a large-scale clinical trial in the United Kingdom in partnership with the National Health Service (NHS).

GRAIL's brand reputation has been influenced by positive cancer test results and the strategic collaboration with Samsung. However, in June 2023, the company faced a reputation challenge due to letters incorrectly sent to patients, and in July 2023, lawsuits were filed by former employees alleging a hostile work environment. Investor sentiment has shown improvement more recently.

Institutional investors hold approximately 69.55% of GRAIL's shares, with major shareholders including CRCM LP, BlackRock, Inc., and Vanguard Group Inc. Illumina, Inc. retains a 12.49% stake in GRAIL. Individual investors hold about 4.26% of the shares.